As part of LakePharma’s ongoing effort to combat the COVID-19 pandemic, we have discovered a large collection of over 350 diverse antibodies against the SARS-CoV-2 spike protein. The SARS-CoV-2 spike protein initiates viral attachment via binding to human angiotensin-converting enzyme 2 (ACE2), thus presenting itself as a crucial candidate for COVID-19 therapeutics, diagnostics, and vaccines.
Following immunization of our immunologically diverse PentaMiceTM, antibodies were obtained using our hybridoma-based antibody recovery workflow. Based on extensive screening assays, LakePharma’s SARS-CoV-2 spike antibodies display a wide range of binding specificities and functional properties. The spike antibodies can be grouped according to reactivity profiles based on binding to the receptor binding domain (RBD) and/or S1 or S2 domains; blocking spike protein binding to the ACE2 receptor; neutralizing SARS-CoV-2 pseudovirus infection of ACE2+TMPRSS2+ target cells; and cross-reactivity (or lack thereof) with spike proteins from other coronaviruses (SARS, MERS, and HKU1).
The various reactivity and functional profiles are consistent with COVID-19 antibody therapy, prevention of SARS-CoV-2 infection, and selective SARS-CoV-2 detection diagnostics. These antibodies are available for licensing for either therapeutic or diagnostic application. If you are interested in augmenting an existing COVID-19 antibody-based therapeutic or diagnostic program, or jumpstarting an early stage proof-of-concept treatment/prevention/detection paradigm, please join the webinar to learn more.